Genetic markers for the diagnosis and prognosis of pheochromocytoma

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 1, 2009, Pages 45-52

  Thouënnon, Erwan ^a   Pierre, Alice ^a   Guillemot, Johann ^a   Yon, Laurent ^a   Eisenhofer, Graeme ^b   Anouar, Youssef ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Gene expression profiling; Marker; Microarray; Pheoochromocytoma; Prognosis; Tumorigenesis

Indexed keywords

ALPHA AMIDATING ENZYME; HYPOXIA INDUCIBLE FACTOR 2ALPHA; NEUROPEPTIDE Y; PHENYLETHANOLAMINE N METHYLTRANSFERASE; PROSTAGLANDIN SYNTHASE; SECRETOGRANIN II; SUCCINATE DEHYDROGENASE; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN;

CARCINOGENESIS; CHROMAFFIN CELL; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENETIC MARKER; HUMAN; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIPPLE SYNDROME; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 69949143442     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.4.1.45     Document Type: Review

References (48)

1. Dahia PL, Ross KN, Wright ME et al. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1(1), 72-80 (2005).
2. Eisenhofer G, Huynh TT, Pacak K et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel - Lindau syndrome. Endocr. Relat. Cancer 11(4), 897-911 (2004).
3. Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab. 90(4), 2110-2116 (2005).
4. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd et al. Clinical experience over 48 years with pheochromocytoma. Ann. Surg. 229(6), 755-764 (1999).
5. Edstrom Elder E, Hjelm Skog AL, Hoog A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur. J. Surg. Oncol. 29(3), 278-283 (2003).
6. Gimenez-Roqueplo AP, Favier J, Rustin P et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 63(17), 5615-5621 (2003).
7. Gao B, Meng F, Bian W et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 68(2), 282-286 (2006).
8. Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol. 26(5), 551-566 (2002).
9. Strong VE, Kennedy T, Al-Ahmadie H et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143(6), 759-768 (2008).
10. Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 23(34), 8812-8818 (2005).
11. Favier J, Kempf H, Corvol P, Gasc JM. Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase. FEBS Lett. 462(1-2), 19-24 (1999).
12. Ballester R, Marchuk D, Boguski M et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63(4), 851-859 (1990).
13. Califano D, Rizzo C, D'Alessio A et al. Signaling through Ras is essential for RET oncogene-induced cell differentiation in PC12 cells. J. Biol. Chem. 275(25), 19297-19305 (2000).
14. Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8(2), 155-167 (2005).
15. Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience 147(4), 928-937 (2007).
16. Powers JF, Tischler AS, Mohammed M, Naeem R. Microarray-based comparative genomic hybridization of pheochromocytoma cell lines from neurofibromatosis knockout mice reveals genetic alterations similar to those in human pheochromocytomas. Cancer Genet. Cytogenet. 159(1), 27-31 (2005).
17. Dahia PL. Evolving concepts in pheochromocytoma and paraganglioma. Curr. Opin. Oncol. 18(1), 1-8 (2006).
18. Dahia PL, Hao K, Rogus J et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res. 65(21), 9651-9658 (2005).
19. August C, August K, Schroeder S et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod. Pathol. 17(9), 1119-1128 (2004).
20. Cascon A, Ruiz-Llorente S, Rodriguez-Perales S et al. A novel candidate region linked to development of both pheochromocytoma and head/ neck paraganglioma. Genes Chromosomes Cancer 42(3), 260-268 (2005).
21. Dannenberg H, Speel EJ, Zhao J et al. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am. J. Pathol. 157(2), 353-359 (2000).
22. Edstrom E, Mahlamaki E, Nord B et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am. J. Pathol. 156(2), 651-659 (2000).
23. Jarbo C, Buckley PG, Piotrowski A et al. Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. Int. J. Cancer 118(5), 1159-1164 (2006).
24. Aarts M, Dannenberg H, deLeeuw RJ et al. Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1-0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer 45(1), 83-93 (2006).
25. Brouwers FM, Eisenhofer G, Tao JJ et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J. Clin. Endocrinol. Metab. 91(11), 4505-4509 (2006).
26. Rao F, Reiser HR, O'Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 36(6), 1045-1052 (2000).
27. Proye C, Fossati P, Fontaine P et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 100(6), 1154-1162 (1986).
28. Eisenhofer G, Goldstein DS, Sullivan P et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J. Clin. Endocrinol. Metab. 90(4), 2068-2075 (2005).
29. John H, Ziegler TO, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 53(4), 679-683 (1999).
30. Thouennon E, Elkahloun AG, Guillemot J et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J. Clin. Endocrinol. Metab. 92(12), 4865-4872 (2007).
31. Yon L, Guillemot J, Montero-Hadjadje M et al. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J. Clin. Endocrinol. Metab. 88(6), 2579-2585 (2003).
32. Guillemot J, Barbier L, Thouennon E et al. Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas. Ann. NY Acad. Sci. 1073, 527-532 (2006).
33. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am. J. Pathol. 161(4), 1235-1246 (2002).
34. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 111(4), 458-464 (2003).
35. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86(11), 5615-5619 (2001).
36. Boltze C, Mundschenk J, Unger N et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J. Clin. Endocrinol. Metab. 88(9), 4280-4286 (2003).
37. Khorram-Manesh A, Ahlman H, Jansson S, Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr. Pathol. 13(2), 99-110 (2002).
38. Salmenkivi K, Arola J, Voutilainen R et al. Inhibin/activin β-subunit expression in pheochromocytomas favors benign diagnosis. J. Clin. Endocrinol. Metab. 86(5), 2231-2235 (2001).
39. Ohta S, Lai EW, Pang AL et al. Downregulation of metastasis suppressor gsnes in malignant pheochromocytoma. Int. J. Cancer 114(1), 139-143 (2005).
40. Gupta D, Shidham V, Holden J, Layfield L. Prognostic value of immunohistochemical expression of topoisomerase-α II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl. Immunohistochem. Mol. Morphol. 8(4), 267-274 (2000).
41. Salmenkivi K, Heikkila P, Haglund C, Louhimo J, Arola J. Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas. Histopathology 43(1), 62-71 (2003).
42. Petri BJ, Speel EJ, Korpershoek E et al. Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Mod. Pathol. 21(4), 407-413 (2008).
43. Benn DE, Gimenez-Roqueplo AP, Reilly JR et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab. 91(3), 827-836 (2006).
44. Amar L, Baudin E, Burnichon N et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 92(10), 3822-3828 (2007).
45. Neumann HP, Pawlu C, Peczkowska M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8), 943-951 (2004).
46. Brouwers FM, Elkahloun AG, Munson PJ et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann. NY Acad. Sci. 1073, 541-556 (2006).
47. Anouar Y, Yon L, Guillemot J et al. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches. Ann. NY Acad. Sci. 1073, 533-540 (2006).
48. Fränkel F. Ein Fall von doppelseitigem, völlig latent verlaufenen nebennierentumor und gleichzeitiger nephritis mit veränderungen am circulationsapparat und retinitis. Arch. Pathol. Anat. Physiol. Klin. Med. 103, 244-263 (1886).